FDA Approves Adstiladrin, Gene Therapy for Tough-to-Treat Bladder Cancer
MONDAY, Dec. 19, 2022 -- The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin (nadofaragene firadenovec-vncg), which is designed to work for patients with high-risk non-muscle-invasive bladder cancer (NMIBC)...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Gene Therapy | General Medicine | Genetics